The Canadian Precision Health Initiative (CPHI) will be the most ambitious genomic health research program in Canadian history and a major milestone for Canada’s health research and innovation ecosystem. This initiative marks the first pillar of a large-scale precision health initiative, aiming to sequence the genomes of at least 100,000 Canadians.
Results Driven Agriculture Research (RDAR) – Genome Alberta Accelerating Agriculture Innovation – One Health Solutions Competition seeks to address pressing issues in Alberta agriculture sector through a One Health approach.
In response to stakeholder consultations across the province, recommendations from post-secondary institutions, and support from the broader research and end-user community, Genome Alberta developed BioNet Alberta for Genome Canada’s Regional Priorities Partnership Program (RP3). BioNet Alberta is a diverse network-based approach to building provincial capacity in the area of bioinformatics and computational biology (B/CB). The
Disease is an economically important trait in Canadian pork production and is one of the most difficult challenges to manage. It also contributes to poor public perception of food animal production in terms of animal welfare, food safety, and antimicrobial resistance. Pig breeding companies (Users) represented by PigGen Canada are the foundation of the Canadian
Application of genomics-based tools to select for pig disease resilience Read More »
The federal contaminated sites inventory lists over 1000 soil and groundwater sites contaminated with BTEX compounds (Benzene, Toluene, Ethylbenzene, and Xylenes). BTEX present significant risks to human and environmental health, especially benzene, a known carcinogen. Benzene is also particularly challenging to remediate due to its slow biodegradation in the absence of oxygen. Genomics-based modeling of
Field validation of technologies for anaerobic benzene and alkylbenzene bioremediation Read More »
Given the competitiveness among the super-majors to find and develop new oil and gas reservoirs around the world, and the billion-dollar cost of exploration programs, any proven enhancements in offshore exploration success will have an immediate economic return. This project focuses on de-risking exploration and development in offshore Nova Scotia by the validation and integration
Genome Canada launched the new challenge-driven Climate Action Genomics Initiative funding opportunity in May 2022.
Genome Canada launched the challenge-driven Climate Action Genomics Initiative funding opportunity in May 2022.
Non-invasive prenatal screening (NIPS) genomics analysis of cell free DNA in maternal blood has the potential to perform well as a first-tier screening test for aneuploidies. NIPS use as a first-tier screening test would simplify, streamline, and enhance the safety of prenatal screening for fetal aneuploidies and could potentially detect other important fetal abnormalities. However,
There are about 7,000 rare genetic diseases (RDs) that affect more than one million Canadians. RDs have a devastating impact on Canadians: two-thirds cause significant disability, three-quarters affect children, more than half lead to early death, and almost all have no treatment. The cause of more than one-third of the 7000 RDs is currently unknown.
Follow Genome Alberta on social media to stay informed, expand your network and discover new resources.
© 2023 Genome Alberta. All rights reserved.
Genome Alberta respectfully acknowledges that our head office is located on Treaty 7 territory of the Blackfoot confederacy, Siksika, Kainai and Piikani First Nations, as well as the Stoney Nakoda and Tsuut’ina First Nations. We acknowledge that this territory is home to the Metis Nation of Alberta, Region 3, within the historical Northwest Metis homeland.
We will continue the work of healing and reconciliation in our communities and look forward to building a path to lead us to a better relationship with Indigenous Peoples and the environment around us based on peace, friendship and respect.
https://genomealberta.ca/project/harnessing-multi-omics-to-deliver-innovative-diagnostic-care-for-rare-genetic-diseases-in-canada-c4r-solve/
